Pancreatic Cancer Research

ResearcherShizuoka UniversityActive in the last 2 years

Daiki Tsuji

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8894-2841; OpenAlex author ID A5047848077. Sources: OpenAlex.

Their work

Papers
5 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 3 papers

Papers 5

  1. Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study. First author DOI 10.1002/bcp.70611↗
  2. Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer. Last author DOI 10.1007/s10147-026-03201-0↗
  3. Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-… First author DOI 10.1007/s10637-026-01632-0↗
  4. Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT s… First author DOI 10.1002/cncr.35343↗
  5. Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine. First author DOI 10.1007/s00228-017-2260-0↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kunihiko Itoh · 5 shared papers, 2017–2026 · strength 0.96
  2. Takashi Yokokawa · 4 shared papers, 2024–2026 · strength 0.89
  3. Masahiro Hatori · 4 shared papers, 2024–2026 · strength 0.89
  4. Naoki Sasahira · 4 shared papers, 2024–2026 · strength 0.89
  5. Masato Ozaka · 3 shared papers, 2026 · strength 0.73
  6. Hiroshi Ishii · 3 shared papers, 2024–2026 · strength 0.63
  7. Ken-ichi Suzuki · 3 shared papers, 2024–2026 · strength 0.63
  8. Aki Otake · 2 shared papers, 2017–2024 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.